OzStar - Advisors

Back-

OzStar Therapeutics

Scientific & Advisory Board Members

Professor Anthony Barnett
Clinical Diabetes - Birmingham, United Kingdom

Professor Anthony Barnett (BSc, MD, FRCP) is Emeritus Professor of Medicine at The
University of Birmingham and a Consultant Physician to one of the largest
diabetes/endocrine units in the UK at the Heart of England NHS Foundation Trust,
Birmingham. Prof Barnett has major research interests in genetics of diabetes and its
microangiopathic complications, aetiology of diabetes vascular disease, pathogenesis of
type 2 diabetes, new drugs for diabetes and its vascular complications and Health Service
related issues including provision of diabetes care in the South Asian population.

Prof Barnett has published over 650 original papers and has edited major text books on
diabetes as well as contributing to the Textbook of Diabetes, International Textbook of
Diabetes and Encyclopaedia of Molecular Biology and Molecular Medicine. In 2011 Prof
Barnett was awarded the Banting Memorial Lecture by Diabetes UK, its highest award to a
person of international standing in diabetes research and in 2012 he was also given the
South Asian Health Foundation & Lifetime Achievement award in recognition of his clinical
and research work in diabetes in people of South Asian extraction. Prof Barnett has acted
as an expert advisor to the UK National Institute for Health and Clinical Excellence (NICE),
National Prescribing Centre and the Committee on Safety of Medicines. He also acted as an
EASD representative advising the European Medicines Agency on diabetes related products.

Professor C. Ronald Kahn
Pre-Clinical and Clinical Diabetes - Boston, United States

Professor C. Ronald Kahn (MD) has played a leading role in diabetes research, including
the discovery of glucagon-like peptide 1 - one of the best anti-diabetes injectable drugs in
the global market. His current research encompasses insulin signal transduction and the
mechanisms of insulin resistance in diabetes, obesity and metabolic syndrome. Prof Kahn is
currently the Chief Academic Officer of the Joslin Diabetes Center and Pre-Clinical and
Clinical Advisor to the company. From 2000-2007, Prof Kahn served as President of the
Joslin Diabetes Center, and under his leadership, Joslin’s research grew more than 20-fold,
with over 700 employees.

Prof Kahn is a founder of Metabio and Ember Therapeutics and has served on the scientific
advisory boards of several biotech companies. He gained a medical degree from the
University of Louisville and after training in internal medicine at Washington University, he
moved to the NIH where he become the Head of the Section on Cellular and Molecular
Physiology of NIDDK.

Professor Lesley Campbell
Clinical Diabetes - Sydney, Australia

Professor Lesley Campbell (MB, BS, MRACP, FRCP(UK), FRACP AM) is a Senior
Endocrinologist in the Diabetes Centre at St Vincent's Hospital, Professor of Medicine,
University of NSW and a Co-director of the Clinical Diabetes, Appetite and Metabolism
Laboratory in the Garvan Institute of Medical Research. She conducts clinical research in
diabetes and insulin resistance, focusing on the underlying causes of type 2 diabetes and
obesity and the aetiology and treatment of Prader Willi Syndrome a genetic disorder of
satiety. She has published over 200 peer-reviewed papers, editing books, manuals, and
writing book chapters. She was a member of the Organising Committee of the 2006
International Congress on Obesity, chaired national and international professional
committees and is a past President of the Australasian Society for the Study of Obesity.

Mr Roger Moore
International Business Development - Sydney, Australia

Mr Roger Moore (BPharm) has over 40 years of experience in the international
pharmaceutical business, including 30 years with Novo Nordisk. He established Novo in
Japan in 1977 and retired as Chairman in 2007. He was Senior Vice President of the Japan
and Oceania Region incl. Australia from 2000-2006, with sales turnover for the Region
exceeding A$1 billion. In 2007 he received a knighthood from the Queen of Denmark for
outstanding services to the state of Denmark especially in relation to Japan.

Professor Sanjoy Paul
Clinical Trial and Biostatistics - Brisbane, Australia

Professor Sanjoy Paul (MS, PhD) is an internationally recognised clinical trialist,
biostatistician and a research administrator with long-standing experience of design and
conduct of clinical trials and pharmaco-epidemiological studies in the fields of metabolic
diseases. Prof. Paul’s current role is Head of the Clinical Trials and Biostatistics Unit (CTBU,
www.qimr.edu.au/ctbu), based at the QIMR Berghofer Medical Research Institute, Australia.
He also holds the Visiting Professorship of the Imperial College London, University of
Warwick and University of Leicester.

He has successfully built up highly productive collaborations with reputed international
institutes and multinational pharmaceutical companies to design and conduct early and late
phase clinical trials in the fields of auto-immune and metabolic diseases. Prof. Paul
continues to play a pivotal role in the development of Australia’s translational research
capabilities as one of the principal members of Therapeutic Innovation Australia. He also has
the privilege of acting as an expert advisor to many clinical and non-clinical studies
conducted by his international academic and industry collaborators.

Mr Raja Rajagopal
Business Development & Capital Raising - Sydney, Australia and Bangalore, India

Mr Ramaswamy (Raja) Rajagopal (BSc, MSc, MBA, ACA) has over twenty-five years of
senior international executive experience as Global Head of Strategy & Business
Development of Novartis Selfmedication Division in Switzerland and as President of Unilever
Technology Ventures, a venture fund based in California. Mr Rajagopal recently served on
the Strategic Advisory Board of SOHO Group, the fourth largest pharmaceutical company in
Indonesia and was a Charter and Board Member in Sydney of TiE, a leading global
organization of entrepreneurs. He has spent a few months each year at CONNECT, the
business incubator in San Diego, as a Business Advisor mentoring start-up companies. He
has served on the Board of start-up companies in life sciences and engineering in Sydney.
Mr Rajagopal has a Bachelor of Technology degree in Chemical Engineering from IIT,
Kanpur, a leading technical institution in India, a Masters in Applied Mechanics and Polymer
Engineering from Imperial College, London and an MBA from Harvard Business School. He
holds a Chartered Accountant qualification earned while working for Price Waterhouse in
London and was subsequently a Manager in the Audit and Consultancy practice of Arthur
Andersen in Barcelona.

Dr Ivan Rajkovic
Intellectual property strategy and protection - Sydney, Australia

Dr Rajkovic joined the patent attorney profession in 1993, after a 17-years career in
biomedical research. He has extensive experience in the intellectual property field, including
drafting patent specifications, patent prosecution, oppositions and litigation support,
intellectual property management and the commercialisation of intellectual property. He is a
frequent speaker at national and international conferences in the field of biotechnology
patenting, commercialisation and IP management.

Dr Rajkovic career in biomedical research comprised over thirteen years post-doctoral
academic research experience and a further four years of commercial research and
development experience. His particular technical expertise lies in the areas of molecular
immunology and oncology, biomolecular engineering, transgenics, gene therapy, microbial
biochemistry, diagnostics and pharmaceuticals. Dr Rajkovic is the author of 45 publications
in peer-reviewed scientific journals in the fields of molecular and cellular biology and
immunology.

Mr Sean Gray
Business Development - Sydney, Australia

Mr Sean Gray (BApplSci, MBA, AACID) has over 10 years experience in leading
commercialising efforts of diabetes technologies. As CEO at AIMEDICS, he developed and
implemented the commercialisation plan of a diabetes technology that non-invasively
detected nocturnal hypoglycaemia. Prior to AIMEDICS, Sean was the General Manager at
Diabetes Australia - NSW where he commercialised a number of diabetes related
technologies, managed large product and service delivery and supported efforts that saw a
number of therapies receive government funding. He is a member of the Australian Institute
of Company Directors, American Diabetes Association and Australian Diabetes Educator
Association. Sean has an MBA from Macquaire Graduate School of Management and a
Bachelor of Applied Science specialising in Agriculture from Massey University.